Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 32, 2019 - Issue 4
Submit an article Journal homepage
55
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Assessing adherence and cost-benefit of colorectal cancer screening for accountable providers

Trace HeavenerDepartment of Internal Medicine, Baylor Scott & White Medical Center–Temple, Temple, Texas; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-1407-8736
, DOORCID Icon,
Frank W. McStayCenter for Healthcare Policy, Baylor Scott & White Medical Center–Temple, Temple, Texas;
, MPA,
Victoria JaegerDepartment of Internal Medicine, Baylor Scott & White Medical Center–Temple, Temple, Texas; ORCID Iconhttp://orcid.org/0000-0002-8583-3081
, DOORCID Icon,
Kristen StephensonDepartment of Internal Medicine, Baylor Scott & White Medical Center–Temple, Temple, Texas;
, MD,
Lauren SagerOffice of Biostatistics, Baylor Scott & White Medical Center–Temple, Temple, Texas;
, MS &
James SingDepartment of Gastroenterology, Baylor Scott & White Medical Center–Temple, Temple, TexasORCID Iconhttp://orcid.org/0000-0001-5563-0104
, DOORCID Icon
Pages 490-497 | Received 08 May 2019, Accepted 18 Jul 2019, Published online: 21 Aug 2019

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi: 10.3322/caac.21387.
  • Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–193. doi: 10.3322/caac.21395.
  • Yabroff KR, Mariotto AB, Feuer E, Brown ML. Projections of the costs associated with colorectal cancer care in the United States, 2000–2020. Health Econ. 2008;17:947–959. doi: 10.1002/hec.1307.
  • Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117–128. doi: 10.1093/jnci/djq495.
  • Abdelsattar ZM, Birkmeyer JD, Wong SL. Variation in Medicare payments for colorectal cancer surgery. J Oncol Pract. 2015;11:391–395. doi:doi: 10.1200/JOP.2015.004036.
  • Luo Z, Bradley CJ, Dahman BA, Gardiner JC. Colon cancer treatment costs for Medicare and dually eligible beneficiaries. Health Care Financ Rev. 2010;31:35–50.
  • Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data. Clin Gastroenterol Hepatol. 2009;7:198–204. doi: 10.1016/j.cgh.2008.08.034.
  • Yabroff KR, Borowski L, Lipscomb J. Economic studies in colorectal cancer: challenges in measuring and comparing costs. J Natl Cancer Inst Monogr. 2013;2013:62–78. doi: 10.1093/jncimonographs/lgt001.
  • Gani F, Cerullo M, Canner JK, et al. Defining payments associated with the treatment of colorectal cancer. J Surg Res. 2017;220:284–292. doi: 10.1016/j.jss.2017.07.021.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi: 10.3322/caac.21332.
  • Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the one million Taiwanese screening program. Cancer. 2015;121:3221–3229. doi: 10.1002/cncr.29462.
  • Zauber AG. Cost-effectiveness of colonoscopy. Gastrointest Endosc Clin N Am. 2010;20:751–770. doi: 10.1016/j.giec.2010.07.008.
  • Dinh T, Ladabaum U, Alperin P, Caldwell C, Smith R, Levin TR. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Clin Gastroenterol Hepatol. 2013;11:1158–1166. doi: 10.1016/j.cgh.2013.03.013.
  • Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA. 2016;315:2595–2609. doi: 10.1001/jama.2016.6828.
  • Patel SS, Kilgore ML. Cost-effectiveness of colorectal cancer screening strategies. Cancer Control. 2015;22:248–258. doi: 10.1177/107327481502200219.
  • Bibbins-Domingo K, Grossman DC, Curry SJ, et al; and the US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2016;315(23):2564–2575. doi: 10.1001/jama.2016.5989.
  • Sheikh RA, Kapre S, Calof OM, Ward C, Raina A. Screening preferences for colorectal cancer: a patient demographic study. South Med J. 2004;97:224–230. doi: 10.1097/01.SMJ.0000078619.39604.3D.
  • Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172:575–582. doi: 10.1001/archinternmed.2012.332.
  • American Cancer Society. Colorectal Cancer Facts & Figures 2017–2019. Atlanta, GA: American Cancer Society; 2017.
  • US Preventive Services Task Force. Final recommendation statement: colorectal cancer: screening. 2016. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/colorectal-cancer-screening2.
  • Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160:171–181. doi: 10.7326/M13-1484.
  • Levy BT, Bay C, Xu Y, et al. Test characteristics of faecal immunochemical tests (FIT) compared with optical colonoscopy. J Med Screen. 2014;21:133–143. doi: 10.1177/0969141314541109.
  • Martin J, Halm EA, Tiro JA, et al. Reasons for lack of diagnostic colonoscopy after positive result on fecal immunochemical test in a safety-net health system. Am J Med. 2017;130:93.e1–93.e7. doi: 10.1016/j.amjmed.2016.07.028.
  • Issaka RB, Singh MH, Oshima SM, et al. Inadequate utilization of diagnostic colonoscopy following abnormal FIT results in an integrated safety-net system. Am J Gastroenterol. 2017;112:375–382. doi: 10.1038/ajg.2016.555.
  • Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening. Ann Intern Med. 2016;164:456–463. doi: 10.7326/M15-0983.
  • Myers RE, Turner B, Weinberg D, et al. Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Prev Med. 2004;38:375–381. doi: 10.1016/j.ypmed.2003.11.010.
  • Oluloro A, Petrik AF, Turner A, et al. Timeliness of colonoscopy after abnormal fecal test results in a safety net practice. J Community Health. 2016;41:864–870. doi: 10.1007/s10900-016-0165-y.
  • Carlson CM, Kirby KA, Casadei MA, Partin MR, Kistler CE, Walter LC. Lack of follow-up after fecal occult blood testing in older adults: inappropriate screening or failure to follow up? Arch Intern Med. 2011;171:249–256. doi: 10.1001/archinternmed.2010.372.
  • Chubak J, Garcia MP, Burnett-Hartman AN, et al. Time to colonoscopy after positive fecal blood test in four US health care systems. Cancer Epidemiol Biomarkers Prev. 2016;25:344–350. doi: 10.1158/1055-9965.EPI-15-0470.
  • Fisher DA, Jeffreys A, Coffman CJ, Fasanella K. Barriers to full colon evaluation for a positive fecal occult blood test. Cancer Epidemiol Biomarkers Prev. 2006;15:1232–1235. doi: 10.1158/1055-9965.EPI-05-0916.
  • Jensen CD, Quinn VP, Doubeni CA, et al. Colonoscopy delay after a positive fecal test and risk of colorectal cancer–related outcomes. Gastroenterology. 2016;150:S45. doi: 10.1016/S0016-5085(16)30276-1.
  • Corley DA, Jensen CD, Quinn VP, et al. Association between time to colonoscopy after a positive fecal test result and risk of colorectal cancer and cancer stage at diagnosis. JAMA. 2017;317:1631–1641. doi: 10.1001/jama.2017.3634.
  • Cyhaniuk A, Coombes ME. Longitudinal adherence to colorectal cancer screening guidelines. Am J Manag Care. 2016;22:105–111.
  • Etzioni DA, Ponce NA, Babey SH, et al. A population-based study of colorectal cancer test use: results from the 2001 California Health Interview Survey. Cancer. 2004;101:2523–2532. doi: 10.1002/cncr.20692.
  • Liss DT, Baker DW. Understanding current racial/ethnic disparities in colorectal cancer screening in the United States: the contribution of socioeconomic status and access to care. Am J Prev Med. 2014;46:228–236. doi: 10.1016/j.amepre.2013.10.023.
  • Wang H, Qiu F, Gregg A, et al. Barriers and facilitators of colorectal cancer screening for patients of rural accountable care organization clinics: a multilevel analysis. J Rural Health. 2018;34:202–212. doi: 10.1111/jrh.12248.
  • Texas Hospital Association. PricePoint—comprehensive query. http://www.txpricepoint.org/Report.aspx. Accessed July 15, 2019.
  • Ko CW, Riffle S, Michaels L, et al. Serious complications within 30 days of screening and surveillance colonoscopy are uncommon. Clin Gastroenterol Hepatol. 2010;8:166–173. doi: 10.1016/j.cgh.2009.10.007.
  • Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100:888–897. doi: 10.1093/jnci/djn175.
  • Zhehui L, Bradley CJ, Dahman BA, Gardiner JC. Colon cancer treatment costs for Medicare and dually eligible beneficiaries. Health Care Financ Rev. 2009;31:35–50.
  • Brenner H, Hoffmeister M, Stegmaier C, et al. Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut. 2007;56:1585–1589. doi: 10.1136/gut.2007.122739.
  • Hassan C, Pickhardt PJ, Kim DH, et al. Systematic review: distribution of advanced neoplasia according to polyp size at screening colonoscopy. Aliment Pharmacol Ther. 2010;31:210–217.
  • Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg. 2002;89:845–860. doi: 10.1046/j.1365-2168.2002.02120.x.
  • Eide TJ. Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer. 1986;38:173–176. doi: 10.1002/ijc.2910380205.
  • Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services. Clin Colon Rectal Surg. 2005;18(03):133–140. doi: 10.1055/s-2005-916274.
  • Martinez ME, Baron JA, Lieberman DA, et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology. 2009;136:832–841. doi: 10.1053/j.gastro.2008.12.007.
  • Coleman HG, Loughrey MB, Murray LJ, et al. Colorectal cancer risk following adenoma removal: a large prospective population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2015;24:1373–1380. doi: 10.1158/1055-9965.EPI-15-0085.
  • Centers for Medicare and Medicaid Services. 2016 Shared Savings Program ACO interactive dataset. https://data.cms.gov/Special-Programs-Initiatives-Medicare-Shared-Savin/2016-Shared-Savings-Program-SSP-Accountable-Care-O/3jk5-q6dr. August 30, 2018.
  • Centers for Medicare and Medicaid Services. 2018 Quality Benchmarks. Baltimore, MD: Centers for Medicare and Medicaid Services; 2017.
  • Schroy PC III, Lal S, Glick JT, Robinson PA, Zamor P, Heeren TC. Patient preferences for colorectal cancer screening: how does stool DNA testing fare? Am J Manag Care. 2007;13:393–400.
  • Lee KS, Park EC. Cost effectiveness of colorectal cancer screening interventions with their effects on health disparity being considered. Cancer Res Treat. 2016;48:1010–1019. doi: 10.4143/crt.2015.279.
  • Wong MC, Ching JY, Chan VC, Sung JJ. The comparative cost-effectiveness of colorectal cancer screening using faecal immunochemical test vs colonoscopy. Sci Rep. 2015;5:13568. doi: 10.1038/srep13568.
  • Mostashari F, Sanghavi D, McClellan M. Health reform and physician-led accountable care: the paradox of primary care physician leadership. JAMA. 2014;311:1855–1856. doi: 10.1001/jama.2014.4086.
  • Kim J, Young L, Bekmuratova S, et al. Promoting colorectal cancer screening through a new model of delivering rural primary care in the USA: a qualitative study. Rural Remote Health. 2017;17:4187. doi: 10.22605/RRH4187.
  • Verma M, Sarfaty M, Brooks D, Wender RC. Population-based programs for increasing colorectal cancer screening in the United States. CA Cancer J Clin. 2015;65:497–510.
  • Mehta SJ, Jensen CD, Quinn VP, et al. Race/ethnicity and adoption of a population health management approach to colorectal cancer screening in a community-based healthcare system. J Gen Intern Med. 2016;31:1323–1330. doi: 10.1007/s11606-016-3792-1.
  • Howard DH. Capsule commentary on Mehta et al. Race/ethnicity and adoption of a population health management approach to colorectal cancer screening in a community-based healthcare system. J Gen Intern Med. 2016;31:1356. doi: 10.1007/s11606-016-3803-2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.